ClinicalTrials.gg
TerminatedNCT00423800Updated Apr 7, 2017Results posted

Efficacy and Safety of 24 vs 48 Weeks of Pegetron® (Peginterferon Alfa-2b + Ribavirin) in Naïve Genotype 1 Hepatitis C (Study P05016)(TERMINATED)

A Phase 3 interventional study of Combination of pegylated interferon alfa-2b (PEG) and ribavirin (RBV) in Hepatitis C, Chronic, sponsored by Merck Sharp & Dohme LLC. Terminated. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2017-04-07.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 3, Interventional, and Treatment

Why this study was terminated
The study was terminated due to difficulty in recruiting participants.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
56
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 40 studies testing peginterferon alfa-2b in Hepatitis C, Chronic — none open to participants now, none under way, none of them phase 3. peginterferon alfa-2b · Hepatitis C, Chronic.

Enrollment
26th of 39
56 · median 99
Started
2006
with 5 others
Phase 3
22 of 40
none open now
Registered
16th of 40
by date
Lead sponsor
25 of 40
Merck Sharp & Dohme LLC

Among the 40 studies testing peginterferon alfa-2b in Hepatitis C, Chronic, this one is the 26th largest by enrollment of the 39 interventional ones that give a count, is one of 6 that started in 2006, is one of 22 in phase 3, and was the 16th registered.

Hepatitis C, Chronic

950 studies on the registry are indexed under Hepatitis C, Chronic; 8 are open to participants now.

Browse Hepatitis C, Chronic studies →

Open to participants now

None of the 40 studies testing peginterferon alfa-2b in Hepatitis C, Chronic is open now. The open studies under Hepatitis C, Chronic, anywhere →

About peginterferon alfa-2b

peginterferon alfa-2b: first FDA approval 2001 (PEGINTRON), first EMA approval 2000. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 5 Hepatitis C, Chronic studies recruiting now, 2 set no upper age limit and 2 stop at 75 or younger; 1 takes children under 18; 1 takes healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 40 studies testing peginterferon alfa-2b in Hepatitis C, Chronic as a file.
02

Study summary

This is a Phase IIIB randomized, controlled, multi-centre, open-label study of 24 versus 48 weeks therapy with Pegetron® (peginterferon alfa-2b + ribavirin) at standard doses in naïve Hepatitis C Virus (HCV) genotype 1 high viral load (HVL) participants who are Hepatitis C Virus-Ribonucleic Acid (HCV-RNA) negative at Week 4. HVL will be defined as HCV-RNA of >600,000 IU/mL prior to the initiation of therapy. Participants with genotype 1 baseline HVL prescribed Pegetron® (peginterferon and ribavirin) in the usual manner in accordance with the marketing authorization and who are viral negative at Week 4 will be randomized at Week 8 to receive a total of 24 or 48 weeks of therapy. Participants will be required to have their baseline and Week-12 viral load analyzed by the same local laboratory using the standard of care test used by the site. Qualitative testing at Week 4, 8, 16-20, 24, and 48 may be conducted either by local laboratory or a central laboratory identified by the sponsor using an assay specified by the sponsor. No additional interventions outside of the clinic's standard of care and the conditions of the Canadian product monograph for Pegetron® will be applied to participants.

03

Conditions studied

  • Hepatitis C, Chronic

Browse trials for

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Must demonstrate willingness to participate in the study.
  • Diagnosed with chronic .
  • Between 18 and 65 years of age of either gender and of any race.
  • a. HCV positive, >600,000 IU/mL at baseline AND b. Genotype 1.
  • Suitable for treatment with Pegetron® per the Canadian product monograph.
  • Investigator has already decided to treat with PEGETRON REDIPEN®

1.5mcg/kg/week of peginterferon alpha-2b plus 800-1200 mg /day of ribavirin.

  • HCV-RNA negative at treatment week 4.
  • Meet certain minimum laboratory values at the week 4 screening visit.
  • Women of and male partners must agree to use a medically accepted method of prior to screening, while receiving protocol-specified medication, and for 6 months after stopping the medication. Acceptable methods of contraception include condoms (male or female) with or without a spermicidal agent, diaphragm or cervical cap with spermicide, medically prescribed IUD, oral or injectable hormonal contraceptive, and surgical sterilization (e.g. hysterectomy or tubal ligation).

Exclusion criteria

Exclusion Criteria:

  • Had previous interferon-based therapy for Chronic .
  • Active virus (HBV) infection.
  • (HIV) antibody positive.
  • Cirrhotic (Stage 4 on Metavir system).
  • Uncontrolled history or current severe depression or psychoses.
  • Uncontrolled epilepsy.
  • Use of illicit drugs.
  • History of non-compliance to medical regimens.
  • Liver disease other than from chronic hepatitis C.
  • Participating in any other clinical study.
  • Used any drugs within 30 days of screening.
  • Participants weighing \< 40 kg or > 125 kg.
  • Pregnant women or women who plan to become pregnant or sexual partners of women who want to become pregnant.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
56 participants (actual)

Study arms

  • Experimental
    Pegetron® - 24 Weeks

    Participants are treated with Pegetron® (pegylated interferon alfa-2b and ribavirin) for 8 weeks and then randomized to an additional 16 weeks of treatment

    Drug: Combination of pegylated interferon alfa-2b (PEG) and ribavirin (RBV)

  • Active comparator
    Pegetron®- 48 Weeks

    Participants are treated with Pegetron® (pegylated interferon alfa-2b and ribavirin) for 8 weeks and then randomized to an additional 40 weeks of treatment.

    Drug: Combination of pegylated interferon alfa-2b (PEG) and ribavirin (RBV)

Interventions

  • DrugCombination of pegylated interferon alfa-2b (PEG) and ribavirin (RBV)

    Drug pages: Peginterferon alfa-2b · Ribavirin

    1. Powder for Solution in Redipen® (pegylated interferon alfa-2b) (80, 100, 120, and 150 microgram strengths), subcutaneous, dose of 1.5 micrograms/kg, weekly for up to 24 or 48 weeks 2. 200 mg ribavirin capsules, oral, weight-based dose of 800, 1000, or 1200 mg, daily for up to 24 or 48 weeks

    Also known as: PEGETRON® combination therapy, (a) SCH 54031, PEGETRON® (peginterferon alfa-2b) Powder for Solution, (b) SCH 18908, PEGETRON® (ribavirin) Capsules

06

What researchers measure

Primary outcomes

  1. Number of Participants With a Sustained Virologic Response

    Participants were tested for the presence of Hepatitis C Virus-Ribonucleic Acid (HCV-RNA) in blood by Qualitative Polymerase Chain Reaction (qPCR). If the HCV-RNA is not detectable, the participant is negative for HCV-RNA. Sustained virologic responders were participants negative for HCV-RNA at 24 weeks following the completion of therapy. A Participant that withdrew prior to 24 weeks following the completion of therapy was considered a non-responder.

    Time frame: 24 weeks following completion of 24 or 48 weeks of therapy

Secondary outcomes

  1. Number of Participants With a Virological Relapse

    Participants were tested for the presence of Hepatitis C Virus-Ribonucleic Acid (HCV-RNA) in blood by Qualitative Polymerase Chain Reaction (qPCR). Virological relapse in participants was defined as having negative virology (HCV-RNA) at end of treatment, but positive virology (HCV-RNA) again at 24 weeks of follow up post treatment.

    Time frame: 24 weeks following completion of 24 or 48 weeks of therapy

07

Results

Posted Feb 23, 2011
Limitations and caveats
Due to the small sample size (n=5), no conclusions should be drawn.

Participant flow

Participant flow — Overall Study
MilestonePegetron® - 24 WeeksPegetron® - 48 Weeks
Started32
Completed31
Not completed01
Withdrew: Protocol violation01

Outcome measures

PrimaryNumber of Participants With a Sustained Virologic Response

Participants were tested for the presence of Hepatitis C Virus-Ribonucleic Acid (HCV-RNA) in blood by Qualitative Polymerase Chain Reaction (qPCR). If the HCV-RNA is not detectable, the participant is negative for HCV-RNA. Sustained virologic responders were participants negative for HCV-RNA at 24 weeks following the completion of therapy. A Participant that withdrew prior to 24 weeks following the completion of therapy was considered a non-responder.

Time frame:
24 weeks following completion of 24 or 48 weeks of therapy
Reported as:
Number · Participants
Number of Participants With a Sustained Virologic Response
ParticipantsPegetron® - 24 WeeksPegetron® - 48 Weeks
Responders31
Non-responders01
SecondaryNumber of Participants With a Virological Relapse

Participants were tested for the presence of Hepatitis C Virus-Ribonucleic Acid (HCV-RNA) in blood by Qualitative Polymerase Chain Reaction (qPCR). Virological relapse in participants was defined as having negative virology (HCV-RNA) at end of treatment, but positive virology (HCV-RNA) again at 24 weeks of follow up post treatment.

Time frame:
24 weeks following completion of 24 or 48 weeks of therapy
Reported as:
Number · Participants
Number of Participants With a Virological Relapse
ParticipantsPegetron® - 24 WeeksPegetron® - 48 Weeks
Participants with Virological Relapse00
Participants with No Virological Relapse31

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Screen Failures—2/2 (100%)0/2 (0%)
Pegetron® - 24 Weeks—0/3 (0%)2/3 (66.7%)
Pegetron® - 48 Weeks—0/2 (0%)1/2 (50%)
Most frequent serious events
Most frequent serious events
EventScreen FailuresPegetron® - 24 WeeksPegetron® - 48 Weeks
GROIN ABSCESSInfections and infestations1/20/30/2
HYPOGLYCAEMIC SEIZUREMetabolism and nutrition disorders1/20/30/2
Most frequent other events
Showing 10 of 23
Most frequent other events
EventScreen FailuresPegetron® - 24 WeeksPegetron® - 48 Weeks
FATIGUEGeneral disorders0/22/30/2
PYREXIAGeneral disorders0/22/30/2
NAUSEAGastrointestinal disorders0/21/31/2
DECREASED APPETITEMetabolism and nutrition disorders0/20/31/2
HYPOAESTHESIANervous system disorders0/20/31/2
AFFECT LABILITYPsychiatric disorders0/20/31/2
INSOMNIAPsychiatric disorders0/21/31/2
DYSPNOEARespiratory, thoracic and mediastinal disorders0/20/31/2
NASAL CONGESTIONRespiratory, thoracic and mediastinal disorders0/20/31/2
OROPHARYNGEAL PAINRespiratory, thoracic and mediastinal disorders0/20/31/2

Baseline characteristics

Age, Continuous
Age, Continuous(years)Pegetron® - 24 WeeksPegetron® - 48 WeeksTotal
Mean54.0 ± 9.522 ± 041.2 ± 18.8
Sex: Female, Male
Sex: Female, Male(Participants)Pegetron® - 24 WeeksPegetron® - 48 WeeksTotal
Female224
Male101
Region of Enrollment
Region of Enrollment(participants)Pegetron® - 24 WeeksPegetron® - 48 WeeksTotal
Canada325
08

Study locations

No study locations are listed for this record.

09

References and documents

Individual participant data

Plan to share: Yes — http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf http://engagezone.msd.com/ds_documentation.php

No publications or documents are linked to this record.

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2006, a primary completion of Oct 2009 and a completion of Oct 2009. It does not say whether these dates are actual or estimated.

Results were first posted in Feb 2011, 1 year 4 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 17, 2007
First posted
Jan 18, 2007
Start
Dec 2006
Primary completionActual
Oct 2009
CompletionActual
Oct 2009
Results first posted
Feb 23, 2011
Last update
Apr 7, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 7, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00423800
Responsible party
Sponsor
First posted
Jan 18, 2007
Start date
Dec 2006
Primary completion
Oct 2009
Completion
Oct 2009
Results posted
Feb 23, 2011
Last update
Apr 7, 2017

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Mar 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Peginterferon alfa-2b · Ribavirin

Start the discussion